AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31942918 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity and Sleep Health (PAS)
Number of subjects: 275
Study 31942918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Health Only (SO)
Number of subjects: 275
Study 31942918 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (CON)
Number of subjects: 275
Study 29290184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulse Light Therapy (IPL) and Triple Combination Cream (TCC)
Number of subjects: 96
Study 29290184 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulse Light Therapy (IPL)
Number of subjects: 96
Study 28349908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaF‐impregnated miswak
Number of subjects: 15
Study 28349908 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush with 1450 ppm fluoride toothpaste
Number of subjects: 15
Study 28349908 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated miswak
Number of subjects: 15
Study 28349908 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush with nonfluoride toothpaste
Number of subjects: 15
Study 26386788 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 1530
Study 26386788 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1530
Study 24123600 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/d
Number of subjects: 344
Study 24123600 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 600 mg/d
Number of subjects: 344
Study 20851499 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-609 (5% acyclovir and 1% hydrocortisone)
Number of subjects: 2437
Study 20851499 — intervention group
Group type: COMPARATOR
Intervention: 5% acyclovir in ME-609 vehicle
Number of subjects: 2437
Study 20851499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ME-609 vehicle)
Number of subjects: 2437
Study 20851499 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-609
Number of subjects: 2437
Study 18359363 — intervention group
Group type: EXPERIMENTAL
Intervention: OPMI TwinEr:YAG laser
Number of subjects: 152
Study 18359363 — intervention group
Group type: COMPARATOR
Intervention: Manual microperforators
Number of subjects: 152
Study 16284710 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtip transducers
Number of subjects: 0
Study 16284710 — intervention group
Group type: EXPERIMENTAL
Intervention: External water pressure transducer catheters
Number of subjects: 0
Study 16284710 — intervention group
Group type: COMPARATOR
Intervention: Microtip and water pressure transducer combination
Number of subjects: 0
Study 16284710 — intervention group
Group type: COMPARATOR
Intervention: Microtip and water pressure transducers
Number of subjects: 0
Study 14674504 — intervention group
Group type: COMPARATOR
Intervention: Group 1: conventional mode (Elipar Highlight)
Number of subjects: 40
Study 14674504 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: step mode (Elipar Highlight)
Number of subjects: 40
Study 14674504 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: ramp mode (Elipar Trilight)
Number of subjects: 40
Study 14674504 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: pulse mode (VIP)
Number of subjects: 40
Study 11306153 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug combination with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) plus nucleoside analogue (NRTI) drugs
Number of subjects: 980
Study 11306153 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combinations (PI followed by NNRTI or NNRTI followed by PI)
Number of subjects: 980
Study 11306153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual NRTI combinations (zidovudine plus lamivudine followed by didanosine plus stavudine or vice versa)
Number of subjects: 980
Study 11306153 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 980
Study 9736326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 2.5 mg daily
Number of subjects: 66
Study 9736326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8279598 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 1100
Study 8279598 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 1100
Study 8279598 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1100
Study 2741861 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg IV every 24 hours)
Number of subjects: 10
Study 2741861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (1 mg/kg IV every 24 hours)
Number of subjects: 10
Study 2741861 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide and ethacrynic acid (alternating doses)
Number of subjects: 10
Study 165796 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep reduction (by awakenings) for three weeks
Number of subjects: 52
Study 165796 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-REM sleep awakenings)
Number of subjects: 52
Study 165796 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride treatment
Number of subjects: 52
Study 30849175 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT (1 of 3 production lots)
Number of subjects: 5003
Study 30849175 — intervention group
Group type: COMPARATOR
Intervention: MMR II
Number of subjects: 5003
Study 30946919 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive leaderboard during intervention phase
Number of subjects: 919
Study 30946919 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no leaderboard)
Number of subjects: 919
Study 28143599 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi OmniCup® ventouse delivery
Number of subjects: 0
Study 28143599 — intervention group
Group type: COMPARATOR
Intervention: Metal cup ventouse delivery
Number of subjects: 0
Study 25582412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling in an MTrP in the lower trapezius muscle
Number of subjects: 72
Study 25582412 — intervention group
Group type: COMPARATOR
Intervention: Dry needling in the lower trapezius muscle but not at an MTrP
Number of subjects: 72
Study 22608271 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional cardiologists (ICs)
Number of subjects: 106
Study 22608271 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lead glasses usage
Number of subjects: 106
Study 22608271 — intervention group
Group type: COMPARATOR
Intervention: Unexposed control group (non-medical workers)
Number of subjects: 106
Study 22008766 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 558
Study 22008766 — intervention group
Group type: COMPARATOR
Intervention: No isoniazid preventive therapy (non-completers)
Number of subjects: 558
Study 18467083 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg astaxanthin
Number of subjects: 132
Study 18467083 — intervention group
Group type: EXPERIMENTAL
Intervention: 16mg astaxanthin
Number of subjects: 132
Study 18467083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 17048421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric levobupivacaine (n = 35)
Number of subjects: 70
Study 17048421 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine (n = 35)
Number of subjects: 70
Study 14592559 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele A455 carriers (HT smokers)
Number of subjects: 90
Study 14592559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G allele carriers (4G/4G homozygotes in HT patients)
Number of subjects: 90
Study 14592559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G/4G smokers
Number of subjects: 90
Study 14592559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G/4G genotype in smokers
Number of subjects: 90
Study 14592559 — intervention group
Group type: COMPARATOR
Intervention: HT patients (general)
Number of subjects: 90
Study 11071403 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100
Study 11071403 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 100
Study 9169311 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 549
Study 9169311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 9169311 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 549
Study 1439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin hydrochloride
Number of subjects: 0
Study 1439274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30795794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha power-maximisation anaesthesia titration strategy during maintenance phase of anaesthesia
Number of subjects: 600
Study 30795794 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cessation of volatile anaesthesia and emergence from an intravenous infusion of propofol during emergence phase of anaesthesia
Number of subjects: 600
Study 30795794 — intervention group
Group type: COMPARATOR
Intervention: Standard care avoiding suppression patterns in the EEG during maintenance phase of anaesthesia
Number of subjects: 600
Study 30795794 — intervention group
Group type: COMPARATOR
Intervention: Standard emergence from volatile anaesthesia only during emergence phase of anaesthesia
Number of subjects: 600
Study 29429537 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing 20 g of soluble fiber dextrin (SFD)
Number of subjects: 41
Study 29429537 — intervention group
Group type: COMPARATOR
Intervention: Beverage containing 0 g of soluble fiber dextrin (control)
Number of subjects: 41
Study 29429537 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing 10 g of soluble fiber dextrin (SFD)
Number of subjects: 41
Study 25307063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 9
Study 25307063 — intervention group
Group type: COMPARATOR
Intervention: Control (chest X-ray or usual care)
Number of subjects: 9
Study 24072776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 44
Study 24072776 — intervention group
Group type: EXPERIMENTAL
Intervention: MASS criteria evaluation after therapy
Number of subjects: 44
Study 24072776 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum LDH levels
Number of subjects: 44
Study 24072776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baseline serum LDH levels and MASS criteria evaluation
Number of subjects: 44
Study 22855276 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-nitro-l-arginine methyl ester (l-NMMA)
Number of subjects: 37
Study 20199883 — intervention group
Group type: COMPARATOR
Intervention: Body composition evaluation using standard anthropometric procedures and CT of the abdomen and mid-femur level.
Number of subjects: 46
Study 20199883 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating lipids measurement, oral glucose tolerance test (OGTT), and hormonal screening including GH secretory capacity (GHRH/arginine test).
Number of subjects: 46
Study 20199883 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of visceral to subcutaneous abdominal fat ratio.
Number of subjects: 46
Study 20199883 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of visceral abdominal fat fraction with subcutaneous fat, BMI, and peak GH-response.
Number of subjects: 46
Study 20199883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh muscle volume assessment.
Number of subjects: 46
Study 20199883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-steroid replacement therapy.
Number of subjects: 46
Study 20199883 — intervention group
Group type: COMPARATOR
Intervention: Comparison of body composition in PWS adults to non-PWS GHD adults.
Number of subjects: 46
Study 18035131 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP treatment
Number of subjects: 21
Study 18035131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15569865 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 2178
Study 15569865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2178
Study 11890429 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment with needles
Number of subjects: 0
Study 11890429 — intervention group
Group type: COMPARATOR
Intervention: Simulated acupuncture using a toothpick in a guidetube
Number of subjects: 0
Study 10396792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive family‐focused interventions with methadone treated parents (33 sessions of family training combined with 9 months of home‐based case management)
Number of subjects: 144
Study 10396792 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no supplemental services)
Number of subjects: 144
Study 8847017 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional immunostimulation and locoregional chemotherapy (Proleukin and Imukin infusion for 10 days, followed by locoregional chemotherapy 15 days later)
Number of subjects: 66
Study 8847017 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy with palliative gastric or biliary bypass (control group)
Number of subjects: 66
Study 1904189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 222
Study 1904189 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior infarction
Number of subjects: 222
Study 1904189 — intervention group
Group type: COMPARATOR
Intervention: Invasive versus conservative treatment strategies
Number of subjects: 222
Study 1904189 — intervention group
Group type: COMPARATOR
Intervention: Early versus delayed beta-blocker therapy
Number of subjects: 222
Study 7020746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine (DEC)
Number of subjects: 20
Study 7020746 — intervention group
Group type: COMPARATOR
Intervention: Topical diethylcarbamazine (DEC) lotion
Number of subjects: 20
Study 31412059 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a decision aid (catalyst)
Number of subjects: 0
Study 31412059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no catalyst)
Number of subjects: 0
Study 28073858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional-dose inactivated poliovirus vaccine (fIPV) administered intradermally on days 0 and 28
Number of subjects: 534
Study 28073858 — intervention group
Group type: COMPARATOR
Intervention: Full-dose inactivated poliovirus vaccine (IPV) administered intramuscularly on days 0 and 28
Number of subjects: 534
Study 28073858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fIPV and IPV
Number of subjects: 534
Study 24975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine as first-line treatment
Number of subjects: 200
Study 24975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone as first-line treatment
Number of subjects: 200
Study 24975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine as second-line treatment after switching
Number of subjects: 200
Study 24975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone as second-line treatment after switching
Number of subjects: 200
Study 24975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both opioids available (per-protocol analysis)
Number of subjects: 200
Study 24975432 — intervention group
Group type: COMPARATOR
Intervention: Adverse reactions to oral morphine
Number of subjects: 200
Study 24975432 — intervention group
Group type: COMPARATOR
Intervention: Adverse reactions to oral oxycodone
Number of subjects: 200
Study 23171815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise augmentation with 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Number of subjects: 0
Study 23171815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise augmentation with 4 KKW for 12 weeks
Number of subjects: 0
Study 23171815 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitor (SSRI) augmentation
Number of subjects: 0
Study 20970246 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained dogs sniffing urine samples from patients with prostate cancer
Number of subjects: 66
Study 20970246 — intervention group
Group type: COMPARATOR
Intervention: Control urine samples from patients with negative biopsies
Number of subjects: 66
Study 19519257 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) applied to the hip area
Number of subjects: 23
Study 19519257 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate transdermal system (MTS) applied to the scapular area
Number of subjects: 23
Study 18269868 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride 3 mg
Number of subjects: 80
Study 18269868 — intervention group
Group type: COMPARATOR
Intervention: Premixed 30 R insulin (70/30) twice‐daily plus glimepiride 3 mg
Number of subjects: 80
Study 15287454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP) targeted therapy
Number of subjects: 17
Study 15287454 — intervention group
Group type: COMPARATOR
Intervention: Intracranial pressure (ICP) targeted therapy
Number of subjects: 17
Study 11241545 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 2000
Study 11241545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2000
Study 9439559 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy-living advice and sulfonylurea therapy
Number of subjects: 1580
Study 8177056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting with exercise (running)
Number of subjects: 116
Study 8177056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting without exercise
Number of subjects: 116
Study 8177056 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary)
Number of subjects: 116
Study 3067699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil with cisplatin
Number of subjects: 283
Study 3067699 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil without cisplatin
Number of subjects: 283
Study 3067699 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reexploration in patients with apparent remission at 12 months
Number of subjects: 283
Study 3067699 — intervention group
Group type: COMPARATOR
Intervention: Patients not subjected to surgical reexploration
Number of subjects: 283
Study 3067699 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reexploration in patients with responding and probably resectable residual disease at 12 months
Number of subjects: 283
Study 31448832 — intervention group
Group type: COMPARATOR
Intervention: 1.2% SMV gel and covering the defect with occlusive membrane (OM)
Number of subjects: 40
Study 31448832 — intervention group
Group type: COMPARATOR
Intervention: 1.2% SMV gel and covering the defect with perforated barrier membranes (PBM)
Number of subjects: 40
Study 31448832 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with occlusive membrane (eOM)
Number of subjects: 40
Study 31448832 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with perforated barrier membranes (ePBM)
Number of subjects: 40
Study 30923972 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-(-)-1-octen-3-ol
Number of subjects: 4
Study 30923972 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-(+) -1-octen-3-ol
Number of subjects: 4
Study 30923972 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 4
Study 28273487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 0
Study 25404537 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 229
Study 25404537 — intervention group
Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonist
Number of subjects: 229
Study 23422652 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily G-CSF administration
Number of subjects: 47
Study 23422652 — intervention group
Group type: COMPARATOR
Intervention: Every other day G-CSF administration
Number of subjects: 47
Study 23422652 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 47
Study 22044774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perborate (Corega Tabs) for 5 min once a day for 6 months
Number of subjects: 45
Study 22044774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 2% for 5 min once a day for 6 months
Number of subjects: 45
Study 22044774 — intervention group
Group type: COMPARATOR
Intervention: Control group - brushing with coconut soap and soft toothbrush
Number of subjects: 45
Study 19796736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 7200
Study 19796736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7200
Study 19796736 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 7200
Study 19796736 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of death, myocardial infarction, and rehospitalization for ACS
Number of subjects: 7200
Study 17029276 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha-2b (IFN1) at a dose of 0.5 million units (MU) given subcutaneously twice daily
Number of subjects: 118
Study 17029276 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose interferon-alpha-2b (IFN5) at a dose of 5 MU given subcutaneously daily
Number of subjects: 118
Study 14990561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phase (HP) after 4 months of OC use at 45% Vo(2 peak)
Number of subjects: 8
Study 14990561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive phase (IP) after 4 months of OC use at 45% Vo(2 peak)
Number of subjects: 8
Study 14990561 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BOC) before OC use at 45% Vo(2 peak)
Number of subjects: 8
Study 14990561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phase (HP) after 4 months of OC use at 65% Vo(2 peak)
Number of subjects: 8
Study 14990561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive phase (IP) after 4 months of OC use at 65% Vo(2 peak)
Number of subjects: 8